These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18494280)

  • 21. [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan].
    Simonenko VB; Medvedev IN; Tolmachev VV
    Klin Med (Mosk); 2011; 89(3):35-8. PubMed ID: 21861401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC
    Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
    [No Abstract]   [Full Text] [Related]  

  • 23. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA; Nuñez JF; Domínguez-Gil A;
    Drugs Aging; 2009; 26(7):617-26. PubMed ID: 19655828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
    Rayner B; Jaeger B; Verboom CN; Pascoe M
    Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
    Maier H; Hehemann K; Vieth M
    Cesk Patol; 2015; 51(2):87-8. PubMed ID: 25970720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome].
    Medvedev IN
    Klin Med (Mosk); 2007; 85(3):29-33. PubMed ID: 17523400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome].
    Medvedev IN; Gromnatskiĭ NI; Golikov BM; Al'-Zuraĭki EM; Li VIu
    Kardiologiia; 2004; 44(10):57-9. PubMed ID: 15477792
    [No Abstract]   [Full Text] [Related]  

  • 29. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K; Hornnes N; Boysen G
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract]   [Full Text] [Related]  

  • 32. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
    Cheng-Lai A
    Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D; Hill MD
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
    Bloch MJ; Basile J
    J Clin Hypertens (Greenwich); 2005 Aug; 7(8):489-92. PubMed ID: 16103761
    [No Abstract]   [Full Text] [Related]  

  • 35. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Normodipin in correction of platelet rheology in hypertensive patients with metabolic syndrome].
    Medvedev IN; Gromnatskiĭ NI
    Ter Arkh; 2005; 77(6):65-8. PubMed ID: 16078604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound.
    Pethig K; Hornig B; Bara C; Schieffer B; Haverich A; Sachse A
    J Int Med Res; 2008; 36(5):1022-31. PubMed ID: 18831897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.